Unknown PHASE1/PHASE2 INTERVENTIONAL NCT00753727

Sunitinib and Radiation in Patients With Resectable Soft-tissue Sarcoma (SUNXRT)

A Phase IB/II Study of Sunitinib in Combination With Neoadjuvant Radiation in Patients With Resectable Soft-tissue Sarcoma

Sponsor: Australasian Sarcoma Study Group

Conditions Soft Tissue Sarcoma

Interventions Radiotherapy Sunitinib malate

Updated 5 times since 2017 Last updated: Jun 21, 2011 Started: Sep 30, 2008 Primary completion: Mar 31, 2012 Completion: Mar 31, 2016

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE1/PHASE2 clinical study on Soft Tissue Sarcoma, this trial is ongoing. The trial is conducted by Australasian Sarcoma Study Group and has accumulated 5 data snapshots since 2008. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Unknown PHASE1/PHASE2
Jul 2024 — Sep 2024 [monthly]

Unknown PHASE1/PHASE2

Status: Unknown Status → Unknown · Phase: PHASE1_PHASE2 → PHASE1/PHASE2
Jan 2021 — Jul 2024 [monthly]

Unknown Status PHASE1_PHASE2
Jun 2018 — Jan 2021 [monthly]

Unknown Status PHASE1_PHASE2
Jan 2017 — Jun 2018 [monthly]

Unknown Status PHASE1_PHASE2

First recorded

Sep 2008

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Australasian Sarcoma Study Group
Peter MacCallum Cancer Centre, Australia
Pfizer

Data source: Australasian Sarcoma Study Group

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Melbourne, Australia